EcoDrugPlus

Potassium Two Pore Domain Channel Subfamily K Member 9

Ensembl ID : ENSBGRG00000024198
Gene Symbol: KCNK9
1 Cross references
215 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSBGRG00000004468
Gene Symbol: KCND3
1 Cross references
261 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily H Member 2

Ensembl ID : ENSBGRG00000004337
Gene Symbol: KCNH2
1 Cross references
253 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSBGRG00000016904
Gene Symbol: KCNQ2
1 Cross references
250 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSBGRG00000021011
Gene Symbol: KCNQ3
1 Cross references
193 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSBGRG00000009774
Gene Symbol: KCNQ5
1 Cross references
200 Possible Orthologues:

Presenilin 1

Ensembl ID : ENSBGRG00000015004
Gene Symbol: PSEN1
1 Cross references
202 Possible Orthologues:

Presenilin 2

Ensembl ID : ENSBGRG00000005715
Gene Symbol: PSEN2
1 Cross references
205 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSBGRG00000024672
Gene Symbol: PSENEN
1 Cross references
185 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSBGRG00000015051
Gene Symbol: PGR
1 Cross references
194 Possible Orthologues:

Prostaglandin D2 Receptor

Ensembl ID : ENSBGRG00000023005
Gene Symbol: PTGDR
1 Cross references
118 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSBGRG00000020949
Gene Symbol: PTGDR2
1 Cross references
205 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).